AURYXIA
Total Payments
$1.6M
Transactions
12,040
Doctors
3,076
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $941,759 | 4,168 | 1,751 |
| 2019 | $608,936 | 7,872 | 2,527 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $694,929 | 73 | 44.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $387,415 | 203 | 25.0% |
| Food and Beverage | $225,188 | 11,478 | 14.5% |
| Travel and Lodging | $112,903 | 266 | 7.3% |
| Consulting Fee | $93,319 | 17 | 6.0% |
| Grant | $25,000 | 1 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $11,940 | 2 | 0.8% |
Payments by Type
General
$855,766
11,967 transactions
Research
$694,929
73 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STUDY OF KRX-0502 (FERRIC CITRATE) DOSE REGIMENS IN SUBJECTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE AND IRON-DEFICIENCY ANEMIA | AKEBIA THERAPEUTICS INC | $265,276 | 0 |
| TRANSITION TO FERRIC CITRATE AMONG HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS | AKEBIA THERAPEUTICS INC | $59,627 | 0 |
| THE RANDOMIZED, PLACEBO CONTROLLED PILOT TRIAL OF USUAL CARE VS. USUAL CARE PLUS AURYXIA IN PD PATIENTS | AKEBIA THERAPEUTICS INC | $10,850 | 0 |
| HOSPITAL CLINICAL PHARMACIST INTERVENTION PROGRAM USING A NOVEL PHOSPHATE BINDER, FERRIC CITRATE (AURYXIA) IN ADULT CHRONIC DIALYSIS PATIENTS | AKEBIA THERAPEUTICS INC | $5,490 | 0 |
Top Doctors Receiving Payments for AURYXIA — Page 6
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Nephrology | Torrance, CA | $266.45 | 20 |
| , MD | Nephrology | Torrance, CA | $265.62 | 18 |
| , M.D | Nephrology | Flushing, NY | $262.12 | 13 |
| , M.D | Nephrology | Mission Viejo, CA | $260.31 | 16 |
| , M.D | Nephrology | Laguna Hills, CA | $259.99 | 13 |
| , M.D | Nephrology | El Paso, TX | $258.81 | 9 |
| , MD | Nephrology | Shreveport, LA | $258.69 | 17 |
| , MD | Nephrology | Spokane, WA | $255.22 | 2 |
| , M.D | Nephrology | Houston, TX | $253.82 | 10 |
| , M.D | Internal Medicine | Montgomery, AL | $250.53 | 7 |
| , M.D | Internal Medicine | Houston, TX | $249.24 | 12 |
| , M.D | Nephrology | Meridian, MS | $248.52 | 2 |
| , MD | Nephrology | Greenville, MS | $246.36 | 14 |
| , MD | Internal Medicine | Knoxville, TN | $246.03 | 13 |
| , MD | Nephrology | Shreveport, LA | $245.90 | 14 |
| , MD | Nephrology | El Paso, TX | $245.17 | 11 |
| , MD | Nephrology | Memphis, TN | $244.01 | 17 |
| , DO | Nephrology | San Antonio, TX | $244.00 | 13 |
| , MD | Student in an Organized Health Care Education/Training Program | East Lansing, MI | $239.22 | 14 |
| , MD | Specialist | Miami, FL | $239.08 | 12 |
| , M.D | Nephrology | Monroe, LA | $238.16 | 19 |
| , MD | Nephrology | Fort Lauderdale, FL | $237.83 | 17 |
| , M.D | Nephrology | Fountain Valley, CA | $237.72 | 12 |
| , MD,FACP | Nephrology | Shreveport, LA | $237.70 | 18 |
| , M.D | Nephrology | Tullahoma, TN | $235.24 | 20 |
Ad
Manufacturing Companies
- AKEBIA THERAPEUTICS INC $1.6M
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 3,076
- Transactions 12,040
About AURYXIA
AURYXIA is a drug associated with $1.6M in payments to 3,076 healthcare providers, recorded across 12,040 transactions in the CMS Open Payments database. The primary manufacturer is AKEBIA THERAPEUTICS INC.
Payment data is available from 2019 to 2020. In 2020, $941,759 was paid across 4,168 transactions to 1,751 doctors.
The most common payment nature for AURYXIA is "Unspecified" ($694,929, 44.8% of total).
AURYXIA is associated with 4 research studies, including "STUDY OF KRX-0502 (FERRIC CITRATE) DOSE REGIMENS IN SUBJECTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE AND IRON-DEFICIENCY ANEMIA" ($265,276).